ADHD Therapeutics Market is expected to reach US$ 64,742.37 million by 2030

Publisher: The Insight Partners

Stimulants Segment Expected to Hold Significant Share of ADHD Therapeutics Market During 2022–2030

According to our new research study on "ADHD Therapeutics Market Forecast (2020–2030), Global and Regional Share, Trend, and Growth Opportunity Analysis," the market is expected to grow from US$ 28,594.55 million in 2022 to US$ 64,742.37 million by 2030; it is anticipated to record a CAGR of 10.8% from 2022 to 2030. Key factors driving the ADHD therapeutics market growth are the growing prevalence of ADHD, increasing patient awareness and treatment-seeking behavior, and rising emphasis on research and development of ADHD therapeutics. However, the side effects associated with ADHD medications and their limited symptomatic relief hinder the market growth.

Attention deficit/hyperactivity disorder (ADHD) is a complex neurodevelopment disorder that affects individuals’ ability to focus, control impulsive behaviors, and manage hyperactivity. It is mostly diagnosed in childhood, but symptoms can persist into adolescence and adulthood. Treatment for ADHD often involves a multidisciplinary approach, including behavioral therapy, education, and medication such as stimulants and non-stimulants.

ADHD Therapeutics Market, by Geography, 2022 (%)

To get free sample copy of the report, along with the TOC, Statistics, and Tables please visit @ https://www.theinsightpartners.com/sample/TIPRE00003833

Source: The Insight Partners Analysis

According to the Morbidity and Mortality Weekly Report (MMWR), published by the Centers for Disease Control and Prevention (CDC) in February 2022, ~6 million children aged 3–17 years in the US were diagnosed with ADHD, accounting for 9.8% of the population between 2016 and 2019. According to an article published by PubMed Central in 2022, ADHD affects 5–7.2% of children and 2.5–6.7% of adults worldwide. According to recent estimates, the frequency of adolescents in the US is much greater, at roughly 8.7% or 5.3 million. Although it has traditionally been thought of as a childhood condition, up to 90% of children diagnosed with ADHD continue to have symptoms in adulthood. It is also possible to diagnose in adults because 75% of individuals with ADHD were not previously diagnosed during childhood, according to a research study. ADHD is frequently associated with comorbid conditions such as anxiety, depression, learning disorders, and substance abuse. The presence of these comorbidities increases the complexity of treatment, necessitating a multi-dimensional approach that addresses both ADHD symptoms and associated conditions. Drugs such as psychostimulants and non-stimulants are recommended, which can assist children in managing their ADHD symptoms in their daily lives and can help regulate behaviors that may cause difficulties in various aspects of their lives, including personal life and academic performance.

Therefore, the high prevalence of ADHD, combined with the increased demand for drugs for treatment, is propelling the ADHD therapeutics market size.

The ADHD therapeutics market analysis has been carried out by considering the following segments: drug type, age group, and distribution channel.

The ADHD therapeutics market, by drug type, is bifurcated into stimulant and non-stimulant drugs. The stimulant drugs segment held a larger market share in 2022 and is anticipated to register a higher CAGR during 2022–2030.

The ADHD therapeutics market, by age group, is segmented into pediatric & adolescent and adult. The pediatric & adolescent segment held the largest ADHD therapeutics market share in 2022. The adult segment is anticipated to register the highest CAGR from 2022 to 2030.

The ADHD therapeutics market, by distribution channel, is segmented into hospital pharmacies, retail pharmacies, and e-commerce. In 2022, the hospital pharmacies segment held the largest market share and is anticipated to register the highest CAGR during 2022–2030.

The scope of the ADHD therapeutics market report focuses on North America (the US, Canada, and Mexico), Europe (Germany, France, Italy, the UK, Spain, and the Rest of Europe), Asia Pacific (Australia, China, Japan, India, South Korea, and the Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America). In 2022, North America held the largest global ADHD therapeutics market share. In the region, the US held the largest share of the market in 2022 and is estimated to continue its dominance from 2022 to 2030. The US has a high prevalence of ADHD, which propels the ADHD therapeutics market growth.

Initiatives taken by key players performing in the global ADHD therapeutics market are listed below:

1. In September 2023, Cingulate Inc. announced results from its Phase 3 study of adult efficacy and safety of its lead candidate, CTx-1301 (dexmethylphenidate), for treating ADHD. The company utilizes Precision Timed Release (PTR), its patented drug delivery platform technology, to build and advance a pipeline of next-generation pharmaceutical products. The results were presented on September 8th at the 36th Annual Psych Congress in Nashville, TN.
2. In March 2022, Noven Pharmaceuticals, Inc., a completely owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., got approval from the US Food and Drug Administration (FDA) for its XELSTRYM (dextroamphetamine) transdermal system, CII, for the treatment of ADHD in adults and pediatric patients aged six years and above.
3. In July 2021, Corium, Inc. launched AZSTARYS. This innovative medication combines Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH) in the US for symptomatic treatment in patients 6 years and older. AZSTARYS got FDA approval in March 2021. It comprises a combination of two types of medication: 70% extended-release prodrug of d-MPH SDX (Schedule IV) and 30% immediate-release d-MPH (Schedule II).
4. In April 2021, Supernus Pharmaceuticals, Inc. announced that the US FDA had approved a Qelbree (viloxazine extended-release capsules) to treat ADHD in patients aged 6–17.

The ADHD therapeutics market analysis is conducted by identifying and evaluating key players in market across different regions. Amneal Pharmaceuticals, Inc; Novartis AG; Pfizer, Inc.; Eli Lilly and Company; Noven Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc; Johnson & Johnson Services, Inc.; Corium Inc; Adlon Therapeutics LP; and Teva Pharmaceutical Industries Ltd. are among the key companies profiled in the ADHD therapeutics market report. The companies have been implementing various strategies that contribute to their growth and led to various changes in the market. The companies utilize organic strategies such as product launches, expansion, and product approvals and inorganic strategies such as collaborations and partnerships.

Contact Us
Contact Person: Content Team 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com